A new study reveals that many promising cancer drugs fail in late-stage clinical trials due to a previously overlooked biological mechanism. Researchers found that tumors can develop resistance by activating alternative signaling pathways, essentially creating biological ‘workarounds’ that render targeted therapies ineffective. This discovery explains why drugs showing strong initial results often disappoint in larger patient populations. The findings suggest that future drug development needs to account for these adaptive resistance mechanisms, potentially through combination therapies or more sophisticated treatment approaches. Read the full article at https://www.sciencedaily.com/releases/2026/04/260409101055.htm